- Home
- SBT vs MRSN Comparison
SBT vs MRSN Comparison
Compare SBT & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBT
- MRSN
- Stock Information
- Founded
- SBT 1984
- MRSN 2001
- Country
- SBT United States
- MRSN United States
- Employees
- SBT N/A
- MRSN N/A
- Industry
- SBT Savings Institutions
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SBT Finance
- MRSN Health Care
- Exchange
- SBT Nasdaq
- MRSN Nasdaq
- Market Cap
- SBT 253.2M
- MRSN 252.0M
- IPO Year
- SBT 2017
- MRSN 2017
- Fundamental
- Price
- SBT $4.86
- MRSN $1.86
- Analyst Decision
- SBT
- MRSN Buy
- Analyst Count
- SBT 0
- MRSN 6
- Target Price
- SBT N/A
- MRSN $6.00
- AVG Volume (30 Days)
- SBT 25.6K
- MRSN 1.1M
- Earning Date
- SBT 01-22-2025
- MRSN 11-13-2024
- Dividend Yield
- SBT N/A
- MRSN N/A
- EPS Growth
- SBT N/A
- MRSN N/A
- EPS
- SBT 0.12
- MRSN N/A
- Revenue
- SBT $67,988,000.00
- MRSN $34,837,000.00
- Revenue This Year
- SBT N/A
- MRSN N/A
- Revenue Next Year
- SBT $6.68
- MRSN N/A
- P/E Ratio
- SBT $40.95
- MRSN N/A
- Revenue Growth
- SBT N/A
- MRSN N/A
- 52 Week Low
- SBT $4.40
- MRSN $1.22
- 52 Week High
- SBT $5.97
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- SBT 55.96
- MRSN 42.16
- Support Level
- SBT $4.81
- MRSN $1.93
- Resistance Level
- SBT $4.86
- MRSN $2.81
- Average True Range (ATR)
- SBT 0.03
- MRSN 0.24
- MACD
- SBT -0.00
- MRSN -0.05
- Stochastic Oscillator
- SBT 57.14
- MRSN 7.79
About SBT Sterling Bancorp Inc.
Sterling Bancorp Inc is a unitary thrift holding company. Its primary business is the operation of its wholly-owned subsidiary, Sterling Bank, through which it offers a range of loan products to the residential and commercial markets, as well as retail banking services. The products and services offered by the bank include saving and current accounts, demand and term deposits, payment cards, trade finance, fund transfer, treasury and cash management. It provides services such as construction loans, residential real estate, commercial real estate, commercial lines of credit and other consumer loans.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.